• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Transgene SA - Product Pipeline Review - H2 2011 Product Image

Transgene SA - Product Pipeline Review - H2 2011

  • Published: November 2011
  • 85 pages
  • Global Markets Direct

Transgene SA – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Transgene SA - Product Pipeline Review - H2 2011” provides data on the Transgene SA’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Transgene SA’s corporate website, SEC filings, investor presentations and featured press releases, both from Transgene SA and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Transgene SA - Brief Transgene SA overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Transgene SA human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, READ MORE >



List of Tables
List of Figures
Transgene SA Snapshot
Transgene SA Overview
Key Information
Key Facts
Transgene SA – Research and Development Overview
Key Therapeutic Areas
Transgene SA – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Transgene SA – Pipeline Products Glance
Transgene SA – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Transgene SA Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Transgene SA–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Transgene SA – Drug Profiles
TG 3003
TG4001
TG4010
TG4023
TG4023 + Flucytosine
TG4040
TG4040 + Pegylated Interferon Alfa-2a + Ribavirin
TG6002
Transgene SA – Pipeline Analysis
Transgene SA – Pipeline Products by Therapeutic Class
Transgene SA - Pipeline Products By Target
Transgene SA – Pipeline Products by Route of Administration
Transgene SA – Pipeline Products by Molecule Type
Transgene SA – Recent Pipeline Updates
Transgene SA - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
TG1042
TG4010
Transgene SA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jul 12, 2010: Transgene Opens First Clinical Site For Phase II Trial Of TG4040 For Treatment Of Chronic Hepatitis C
Nov 07, 2011: Transgene And Jennerex Announce Final Data At AASLD From JX594/TG6006 Randomized Phase II Clinical Trial Showing Statistically Significant Survival Benefit In Patients With Advanced Liver Cancer
Nov 07, 2011: Transgene's Therapeutic HCV Vaccine TG4040 Combined With Commonly Used Treatment Achieves Substantial Viral Suppression In Randomized Phase II Trial
Sep 01, 2010: Transgene Receives Positive EMA Scientific Advice For Phase IIb/III Trial Of TG4010 For Treatment Of Non-Small Cell Lung Cancer
Financial Deals Landscape
Transgene SA, Deals Summary
Transgene SA, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Jenrin Discovery Secures $3 Million In Financing
Jenrin Discovery Secures Seed Financing
Partnerships
Innate Pharma And Transgene Form Platine Pharma Services
Transgene Signs Agreement With Beckman Coulter
Transgene Enters Into Collaboration With Ventana Medical Systems
Tianjin Tasly Forms Joint Venture With Transgene
Transgene Enters Into Collaboration Agreement With National Cancer Institute
Licensing Agreements
ISA Pharmaceuticals Enters Into Licensing Agreement With Transgene
Virax Holdings Enters Into Licensing Agreement With Transgene For Skin Cancer Drug
Jennerex Enters Into Licensing Agreement With Transgene For JX-594
Transgene Enters Into Option Licensing Agreement With Novartis
Crucell Enters Into Licensing Agreement With Transgene
Roche Enters Into Licensing Agreement With Transgene
Virax Holdings Enters Into Licensing Agreement With Transgene
Equity Offering
Transgene Completes Rights Offering For $228 Million
Transgene Completes Public Offering Of $134 Million
Transgene Raises $18 Million From Exercise Of Warrants
Transgene Raises $4 Million From Exercise Of Warrants
Transgene Completes Public Offering Of $42 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Transgene SA – Pipeline by Therapy Area and Indication, H2 2011
Transgene SA – Pipeline by Stage of Development, H2 2011
Transgene SA – Monotherapy Products in Pipeline, H2 2011
Transgene SA – Combination Treatment Modalities in Pipeline, H2 2011
Transgene SA – Phase III, H2 2011
Transgene SA - Phase II, H2 2011
Transgene SA - Phase I, H2 2011
Transgene SA - Pipeline By Therapeutic Class, H2 2011
Transgene SA - Pipeline By Target, H2 2011
Transgene SA – Pipeline By Route of Administration, H2 2011
Transgene SA – Pipeline By Molecule Type, H2 2011
Transgene SA – Recent Pipeline Updates, H2 2011
Transgene SA - Discontinued Pipeline Products, 2010
Transgene SA, Subsidiaries
Transgene SA, Deals Summary
Jenrin Discovery Secures $3 Million In Financing
Jenrin Discovery Secures Seed Financing
Innate Pharma And Transgene Form Platine Pharma Services
Transgene Signs Agreement With Beckman Coulter
Transgene Enters Into Collaboration With Ventana Medical Systems
Tianjin Tasly Forms Joint Venture With Transgene
Transgene Enters Into Collaboration Agreement With National Cancer Institute
ISA Pharmaceuticals Enters Into Licensing Agreement With Transgene
Virax Holdings Enters Into Licensing Agreement With Transgene For Skin Cancer Drug
Jennerex Enters Into Licensing Agreement With Transgene For JX-594
Transgene Enters Into Option Licensing Agreement With Novartis
Crucell Enters Into Licensing Agreement With Transgene
Roche Enters Into Licensing Agreement With Transgene
Virax Holdings Enters Into Licensing Agreement With Transgene
Transgene Completes Rights Offering For $228 Million
Transgene Completes Public Offering Of $134 Million
Transgene Raises $18 Million From Exercise Of Warrants
Transgene Raises $4 Million From Exercise Of Warrants
Transgene Completes Public Offering Of $42 Million

List of Figures
Transgene SA – Pipeline by Therapy Area and Indication, H2 2011
Transgene SA – Pipeline by Stage of Development, H2 2011
Transgene SA – Monotherapy Products in Pipeline, H2 2011
Transgene SA – Combination Treatment Modalities in Pipeline, H2 2011
Transgene SA – Pipeline By Therapeutic Class, H2 2011
Transgene SA - Pipeline By Target, H2 2011
Transgene SA – Pipeline By Route of Administration, H2 2011
Transgene SA – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS